Bartziokas Kostantinos, Papaporfyriou Anastasia, Hillas Georgios, Papaioannou Andriana I, Loukides Stelios
Pulmonologist, Trikala, Greece.
2nd Respiratory Medicine Department, "Attikon" University Hospital, Athens, Greece.
Postgrad Med. 2023 May;135(4):327-333. doi: 10.1080/00325481.2022.2135893. Epub 2022 Oct 19.
Chronic obstructive pulmonary disease (COPD) is already the third leading cause of death worldwide and simultaneously a major cause of morbidity and mortality. Global initiative for Chronic Obstructive Lung Disease (also known as GOLD) committee, has been created in 1997 to increase the awareness regarding the burden of COPD. GOLD recommendations have been contributing to diagnosis, managementz, and therapy of COPD since 2001. Through these years, by reviewing published articles, GOLD aimed to provide state-of-the-art information not only for pulmonologists, but also for non-respiratory physicians, and to encourage research on COPD. From 2011, GOLD annual reports have changed the way of COPD evaluation from based entirely on spirometric parameters to more clinical indices, such as the assessment of symptoms and dyspnea alongside with exacerbations. Moreover, according to recent developments in pathophysiology of COPD, there is a trend in identifying new preclinical stages, contributing to prevention and early COPD treatment. In the field of therapeutic algorithms, changes turn to a more personalized approach. However, it is not clear in what extent this personalized disease management would be feasible and the real challenge for current recommendations is to include more patient characteristics such as comorbidities and multidimensional scores in disease evaluation.
慢性阻塞性肺疾病(COPD)已是全球第三大死因,同时也是发病和死亡的主要原因。全球慢性阻塞性肺疾病倡议组织(也称为GOLD)委员会于1997年成立,以提高对COPD负担的认识。自2001年以来,GOLD指南一直在为COPD的诊断、管理和治疗提供帮助。这些年来,通过回顾已发表的文章,GOLD旨在不仅为肺科医生,也为非呼吸内科医生提供最新信息,并鼓励对COPD进行研究。从2011年起,GOLD年度报告将COPD评估方式从完全基于肺功能参数转变为更多的临床指标,如症状评估、呼吸困难评估以及急性加重情况。此外,根据COPD病理生理学的最新进展,存在识别新的临床前期阶段的趋势,这有助于COPD的预防和早期治疗。在治疗方案领域,转变为更个性化的方法。然而,这种个性化疾病管理在多大程度上可行尚不清楚,当前指南面临的真正挑战是在疾病评估中纳入更多患者特征,如合并症和多维评分。